Место статинов и антагонистов кальция в первичной и вторичной профилактике ишемического инсульта
- Авторы: Смоленская О.Г1,2
-
Учреждения:
- Уральская государственная медицинская академия
- Городская больница №41, Екатеринбург
- Выпуск: Том 9, № 2 (2007)
- Страницы: 72-78
- Раздел: Статьи
- URL: https://bakhtiniada.ru/2075-1753/article/view/92354
- ID: 92354
Цитировать
Полный текст
Аннотация
Полный текст
Открыть статью на сайте журналаОб авторах
О. Г Смоленская
Уральская государственная медицинская академия; Городская больница №41, Екатеринбург
Список литературы
- Гусев Е.И. Проблема инсульта в России. Журн. неврол. и психиат. (Прил. "Инсульт") 2003; 9: 3-7.
- The PHYLLIS project group. Plaque Hypertension Lipid - Lowering Italian Study (PHYLLIS): a protocol for non - invasive evaluation of carotid atherosclerosis in hypercholesterolaemic hypertensive subjects. J Hypertens 1993; 11 (Suppl. 5): S314-5.
- Скворцова В.И., Стаховская Л.В., Айриян Н.Ю. Проблема инсульта в Российской Федерации. Сердце. 2005; 6: 309-11.
- Asymptomatic Carotid Atherosclerosis Study. JAMA 1995; 273: 1421-8.
- Dijk J.M, van der Graat G, Bots M.L et al. Carotid intima - media thickness and the risk of new vascular events in patients with manifest atherosclerotic disease: the SMART study. Eur Heart J 2006; 24: 1971-8.
- Waters D.D, Schwartz G.G, Olsson A.G et al. Effects of atorvastatin on stroke in patients with unstable angina or non - Q - wave myocardial infarction. Circulation 2002; 106: 1695-5.
- Athyros V.G, Papageorgiou A.A, Mercouris B.R et al. Treatment with atorvastatin to the National Cholesterol Education Program goal versus "usual" care in secondary coronary heart disease prevention. Cur Med Res Opin 2002; 18: 220-8.
- Taylor A.J, Kent S.M, Flaherty P.J et al. ARBITER: Arterial Biology for the Investigation on the Treatment Effects of Reducing Cholesterol. Circulation 2002; 106: 2055-60.
- Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range in initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
- Stamler J, Wentworth D, Neaton J.D et al. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 365222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986; 256: 2823-8.
- Broedl U.C, Geiss A-C, Parhofer K.G, Comparison of current guidelines for primary prevention of coronary disease. J Gen Intern Med 2003; 18: 190-5.
- Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации, 2-й пересмотр. ВНОК, Секция артериальной гипертензии, 2004.
- Mac Mahon S, Peto R, Cutler J et al. Blood pressure, stroke and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observation studies corrected for the regression dilution bias. Lancet 1990; 335: 765-74.
- Kjeldsen S.E. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension. JAMA 2002; 288: 1491-8.
- Dahlof B, Sever P.S, Poulter N.R. For the ASCOT investigator. Prevention of cardiovascular events with a antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required in the Anglo-Scandinavian Cardiac Outcomes Trial. Lancet 2005; 366: 895-906.
- Sever P.S, Dahlof B, Poulter N.R et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower - then - average cholesterol concentration, in the Anglo - Scandinavian Cardiac Outcomes Trial - Lipid Lowering Arm (ASCOT - LLA): a multicentre randomized controlled trial. Lancet 2003; 361: 1149-58.
- Ballantyne C.M. Changing lipid - lowering guidelines: whom to treat and how low to go. Eur Heart J 2005; 7 (suppl. A): A13-A19.
- Pitt B, Byington R.P, Furberg C.D et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. Circulation 2000; 102: 1503-10.
- High-Dose Atorvastatin after Stroke or Transient Ischemic Attack. The Stroke High - Dose Atorvastatin after Stroke or Transient Ischemic Attack. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. N Engl J Med 2006; 355: 549-59.
- Sever P.S, Dahlof B, Poulter N.R et al. Potential synergy between lipid - lowering and blood - pressure - lowering in the Anglo - Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006; 24: 2982-8.
- Henry P.D. Calcium Channel Blockers and Atherosclerosis. J Cardiovasc Pharmacol 1990; 16 (Suppl. 1): S12-S15.
- Nissen S.E, Murat Tuzcu E, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure. The CAMELOT Study: a randomized controlled trial. JAMA 2004; 292: 2217-25.
- Sever P.S. Lipid - lowering Therapy and the Patients with Multiple Risk Factor: What Have We Learned from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). Am J Med 2005; 118 (Suppl. 12A): 3S-9S.
- Cholesterol Treatment Trialists (CTT) Collaboration. Efficacy and safety of cholesterol - lowering treatment: prospective meta - analysis of data from 90056 participants in 14 randomized trials of statins. Lancet 2005; 366: 1267-78.
- Poulter N.R, Wedel H, Dahlof B et al. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005; 366: 907-13.
Дополнительные файлы
